Omega therapeutics stock.

Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines. The Company's OMEGA platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an …Get the latest Omega Therapeutics, Inc. (OMGA) stock news and headlines to help you in your trading and investing decisions.OMEGA THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 68217N 105 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering . 55 Cambridge Parkway, Suite 800E . Cambridge, MA 02142 (617) 868-1888 (Name, Address and Telephone Number of Person Authorized to Receive Notices and ...Stock Price Forecast The 6 analysts offering 12-month price forecasts for Omega Therapeutics Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 10.00.

On average, Wall Street analysts predict. that Omega Therapeutics's share price could reach $12.00 by Nov 13, 2024. The average Omega Therapeutics stock price prediction forecasts a potential upside of 552.17% from the current OMGA share price of $1.84.The latest price target for Omega Therapeutics ( NASDAQ: OMGA) was reported by HC Wainwright & Co. on Monday, November 13, 2023. The analyst firm set a price target for …Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences.

If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Omega Therapeutics Inc stock performance at a glance. Check Omega Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

Omega Therapeutics Inc’s ( OMGA) price is currently up 41.96% so far this month. During the month of April, Omega Therapeutics Inc’s stock price has reached a high of $8.95 and a low of $5.76. Over the last year, Omega Therapeutics Inc has hit prices as high as $11.98 and as low as $1.98. Year to date, Omega Therapeutics Inc’s stock is ...Omega Therapeutics Inc Stock Price History. Omega Therapeutics Inc’s price is currently down 17.71% so far this month. During the month of August, Omega Therapeutics Inc’s stock price has reached a high of $5.55 and a low of $4.56. Over the last year, Omega Therapeutics Inc has hit prices as high as $11.98 and as low as $3.88. Year to date ...Omega Therapeutics, Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Ascendis Pharma A/S (ASND), another stock in the same industry, closed the last trading session 1.1% ...12 hours ago · CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the H.C. Wainwright 4 th Annual Precision Oncology Virtual Conference on Wednesday, December 6 ... The Omega Therapeutics, Inc. stock prediction for 2025 is currently $ 1.147360, assuming that Omega Therapeutics, Inc. shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -49.90% increase in the OMGA stock price. Omega Therapeutics, Inc. Stock Prediction 2030.

Apr 18, 2023 · Omega Therapeutics Inc Stock Price History. Omega Therapeutics Inc’s price is currently up 41.96% so far this month. During the month of April, Omega Therapeutics Inc’s stock price has reached a high of $8.95 and a low of $5.76. Over the last year, Omega Therapeutics Inc has hit prices as high as $11.98 and as low as $1.98. Year to date ...

Omega Therapeutics, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Castle Biosciences, Inc. (CSTL), finished the last trading ...

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences.SFRP1. Alopecia. EC: Epigenomic Controller. Route of Administration (top to bottom): IV (HCC), IV (NSCLC), IV (SCLC), IV/Pulmonary, IV/Pulmonary (IPF), IV (Liver regeneration), Topical (Corneal regeneration), Topical (Alopecia) *In November 2022, OTX-2002 received Orphan Drug Designation from the FDA for the treatment of hepatocellular ...CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of ...Corporate Profile. Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes ...Oct 16, 2023 · CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data supporting the potential of OTX-2101, a c-MYC-targeting epigenomic controller ... Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of -3.23% and 13.08%, respectively, for the quarter ended December 2022. ... Seres Therapeutics (MCRB), another stock in ...Within the last quarter, Omega Therapeutics (NASDAQ:OMGA) has observed the following analyst ratings: These 4 analysts have an average price target of $10.75 versus the current price of Omega ...

Omega Therapeutics, Inc. (OMGA) delivered earnings and revenue surprises of 21.88% and 31.20%, respectively, for the quarter ended March 2023. ... Revance Therapeutics, Inc. (RVNC), another stock ...Investors Analyst Coverage. Analyst Coverage. Omega Therapeutics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Omega Therapeutics’ performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Omega Therapeutics or its management.Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock. CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today …Description. Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using the epigenomic controllers, Omega is seeking to transform the practice of human ... Mar 31, 2023 · Within the last quarter, Omega Therapeutics (NASDAQ:OMGA) has observed the following analyst ratings: These 4 analysts have an average price target of $10.75 versus the current price of Omega ... Nov 15, 2023 · The Investor Relations website contains information about Omega Therapeutics's business for stockholders, potential investors, and financial analysts.

Omega Therapeutics has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Ignyte Acquisition has a beta of 0.19, indicating that its stock price ...

Omega Therapeutics (OMGA) entered into a securities purchase agreement with investors for offering 6.9M shares at a purchase price of $5.78/share leading to gross proceeds of ~$40M.Offer...Get the latest Omega Therapeutics Inc (OMGA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Feb 23, 2023 · Omega Therapeutics, Inc. 2.2400. -0.0500. -2.18%. CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company ... Omega Therapeutics Inc stock performance at a glance. Check Omega Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing ™ platform, …Omega Therapeutics, Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Castle Biosciences, Inc. (CSTL), finished the last trading ...Omega Therapeutics Stock Price | OMGA Stock Quote, News, and History | Markets Insider The word "Insider". Markets Stocks Indices Commodities …

Comparatively, Omega Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PLX or OMGA? 12.5% of Protalix BioTherapeutics shares are held by institutional investors.

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of ...

Jun 29, 2023 · The consensus mark for Omega Therapeutics has narrowed from a loss of $2.49 per share to a loss of $2.05 for 2023 in the past 90 days. Shares of the company have rallied 2.2% year to date. Omega stock options eligibility upon hire and annually Employee Assistance Program 24/7 access to support employees and their families “I am motivated to work at Omega Therapeutics because I share the company’s vision of creating epigenomic medicines that can treat serious diseases. I am inspired by the breakthrough science and the visionary …OMEGA Epigenomic Programming Platform: Omega is creating a new generation of programmable mRNA therapeutics, one that is designed to enable control of fundamental epigenetic processes to correct ...Nov 24, 2023 · Comparatively, Omega Therapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PLX or OMGA? 12.5% of Protalix BioTherapeutics shares are held by institutional investors. Advanced Company’s Lead Program, OTX-2002, in the Clinic; Preliminary Data from Phase 1/2 MYCHELANGELO™ I Trial Anticipated in 2023 Progressed IND-enabling Studies for OTX-2101; Company’s ...The latest price target for Omega Therapeutics ( NASDAQ: OMGA) was reported by HC Wainwright & Co. on Monday, November 13, 2023. The analyst firm set a price target for 12.00 expecting OMGA to ...Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company’s OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular ...Omega Therapeutics last released its quarterly earnings results on November 9th, 2023. The reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.16. The company earned $0.83 million during the quarter, compared to the consensus estimate of $0.75 million.

Omega Therapeutics, Inc. - Hold. Zacks' proprietary data indicates that Omega Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the OMGA shares ...Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Omega Therapeutics Inc have a median target of 12.00, with a high estimate of 15.00 and a low estimate of 10.00. The ... CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the third quarter ended September 30, 2023, and …Omega Therapeutics Inc (OMGA) has experienced a 24.46% rise in stock performance for the past week, with a 67.15% rise in the past month, and a -37.60% drop in the past quarter. The volatility ratio for the week is 10.97%, and the volatility levels for the past 30 days are at 14.09% for OMGA.Instagram:https://instagram. webull index fundspacer cash cowss and p 500 holdingsbest funded trader programs OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform. CAMBRIDGE, Mass., Oct. 12, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging ...Currently, Omega Therapeutics Inc [OMGA] is trading at $2.29, up 27.22%. An important factor to consider is whether the stock is rising or falling in short-term value. The OMGA shares have gain 24.46% over the last week, with a monthly amount glided 67.15%, and seem to be holding up well over a long-time horizon. On ai for stockstipx dividend Omega Therapeutics Inc Stock Price History. Omega Therapeutics Inc’s price is currently up 0.77% so far this month. During the month of March, Omega Therapeutics Inc’s stock price has reached a high of $9.80 and a low of $6.01. Over the last year, Omega Therapeutics Inc has hit prices as high as $11.98 and as low as $1.98. Year to date ...Foundational Science. Epigenetics is nature’s fundamental mechanism for gene control and cell differentiation. Through the pioneering research of our founding scientific advisors and our own work, we have developed a deep understanding of gene regulation, genomic architecture and epigenetic mechanisms, which guides our approach to creating a ... nvidia earnings expectations The latest price target for Omega Therapeutics ( NASDAQ: OMGA) was reported by HC Wainwright & Co. on Monday, November 13, 2023. The analyst firm set a price target for …5 Wall Street research analysts have issued 1-year price targets for Omega Therapeutics' shares. Their OMGA share price targets range from $10.00 to $12.00. On average, they expect the company's stock price to reach $11.40 in the next twelve months. This suggests a possible upside of 551.4% from the stock's current price.